The Albumin in Subarachnoid Hemorrhage (ALISAH) multicenter pilot clinical trial: safety and neurologic outcomes

Human albumin has been shown to exert neuroprotective effects in animal models of cerebral ischemia and humans with various intracranial pathologies. We investigated the safety and tolerability of 25% human albumin in patients with subarachnoid hemorrhage. The Albumin in Subarachnoid Hemorrhage (ALI...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Stroke (1970) Ročník 43; číslo 3; s. 683
Hlavní autori: Suarez, Jose I, Martin, Renee H, Calvillo, Eusebia, Dillon, Catherine, Bershad, Eric M, Macdonald, R Loch, Wong, John, Harbaugh, Robert
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 01.03.2012
Predmet:
Acute Disease
Adult
Aged
Albumins - adverse effects
Albumins - therapeutic use
Blood Pressure - physiology
Cardiovascular Diseases - chemically induced
Cardiovascular Diseases - epidemiology
Data Interpretation, Statistical
Disability Evaluation
Dose-Response Relationship, Drug
Female
Follow-Up Studies
Glasgow Outcome Scale
Humans
Male
Middle Aged
Nervous System Diseases - etiology
Nervous System Diseases - prevention & control
Neuroprotective Agents - adverse effects
Neuroprotective Agents - therapeutic use
Patient Care Management
Pilot Projects
Respiratory Tract Diseases - chemically induced
Respiratory Tract Diseases - epidemiology
Sample Size
Subarachnoid Hemorrhage - complications
Subarachnoid Hemorrhage - drug therapy
Subarachnoid Hemorrhage - psychology
Treatment Outcome
ISSN:1524-4628, 1524-4628
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Human albumin has been shown to exert neuroprotective effects in animal models of cerebral ischemia and humans with various intracranial pathologies. We investigated the safety and tolerability of 25% human albumin in patients with subarachnoid hemorrhage. The Albumin in Subarachnoid Hemorrhage (ALISAH) Pilot Clinical Trial was an open-label, dose-escalation study. We intended to study 4 different dosages of albumin of increasing magnitude (0.625 g/kg: Tier 1; 1.25 g/kg: Tier 2; 1.875 g/kg: Tier 3; and 2.5 g/kg: Tier 4). Each dosage was to be given to 20 adult patients. Treatment was administered daily for 7 days. We investigated the maximum tolerated dose of albumin based on the rate of severe-to-life-threatening heart failure and anaphylactic reaction and functional outcome at 3 months. We treated 47 adult subjects: 20 in Tier 1; 20 in Tier 2; and 7 in Tier 3. We found that doses ranging up to 1.25 g/kg/day×7 days were tolerated by patients without major dose-limiting complications. We also found that outcomes trended toward better responses in those subjects enrolled in Tier 2 compared with Tier 1 (OR, 3.0513; CI, 0.6586-14.1367) and with the International Intraoperative Hypothermia for Aneurysm Surgery Trial cohort (OR, 3.1462; CI, 0.9158-10.8089). Albumin in doses ranging up to 1.25 g/kg/day×7 days was tolerated by patients with subarachnoid hemorrhage without major complications and may be neuroprotective. Based on these results, planning of the ALISAH II, a Phase III, randomized, placebo-controlled trial to test the efficacy of albumin, is underway. URL: http://clinicaltrials.gov. Unique identifier: NCT00283400.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1524-4628
1524-4628
DOI:10.1161/STROKEAHA.111.633958